Lyka Labs Limited

MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49
Website : lykalabs.com • Email : enquiry @ lykalabs.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st DECEMBER 2012

(Rs in Lacs)

Particular	3 Months Ended 31-Dec-2012 (Unaudited)	Previous 3 Months Ended 30-Sep-2012 (Unaudited)	Corresponding 3 Month ended in the Previous period ended 31-Dec-2011 (Unaudited)	Year to date figure for Current year Ended 31-Dec- 2012 (9 Months) (Unaudited)	Year to date figure for Previous period Ended 31/12/2011 (15 Months) (Unaudited)	Previous Accounting year Ended 31-Mar-2012 (18 Months) (Audited)
1 Income from operations						
(a) Net Sales/Income from operations (Net of excise duty)	2097.68	2292.05	1713.60	6369.53	11243.24	13419.27
(b) Other Operating Income	115.95	104.35	113.92	362.46	482.74	561.90
Total income from operations (net)	**2,213.63**	**2,396.40**	**1,827.52**	**6,731.99**	**11725.98**	**13981.17**
2 Expenses						
(a) Cost of Materials Consumed	1221.66	1115.66	881.20	3,265.20	5445.95	6744.15
(b) Purchase of traded goods	212.92	375.64	150.16	814.75	2367.66	2687.58
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	-117.05	111.60	106.89	54.38	-32.44	-172.13
(d) Employee benefits expense	281.79	252.95	252.89	799.89	1414.03	1687.22
(e) Depreciation and amortisation expense	80.79	82.00	90.23	240.80	449.78	545.89
(f) Other expenses	365.07	336.38	318.31	1066.71	1788.48	2209.73
Total expenses	**2045.18**	**2274.23**	**1799.67**	**6241.73**	**11433.45**	**13702.44**
3 Profit/(Loss) from Operations before Other Income,Finance cost and Exceptional items (1-2)	168.45	122.17	27.85	490.26	292.53	278.73
4 Other Income	68.14	117.17	62.44	235.72	300.65	533.13
5 Profit/(Loss) from ordinary activities before finance cost and exceptional Items (3±4)	**236.59**	**239.34**	**90.29**	**725.98**	**593.18**	**811.86**
6 Finance costs	372.35	372.11	448.98	1112.79	1887.26	2255.52
7 Profit/(Loss) from ordinary activities after finance cost but before exceptional Items (5±6)	**-135.76**	**-132.77**	**-358.69**	**-386.81**	**-1294.07**	**-1443.66**
8 Exceptional Items (Net)						
a Profit on Sale of Fixed Assets	-	-	134.34	-	134.34	884.65
b Foreign Currency Monetary Item Translation	-	-	138.24	-		
c Amortization of Expenses for restructring	-12.49	-12.48		-37.46		-12.49
d Excess provision written back	-	-		62.21		-
Total Exceptional items(Net)	**-12.49**	**-12.48**	**272.58**	**24.75**	**134.34**	**872.16**
9 Profit/(Loss) from Ordinary Activities before tax (7±8)	**-148.25**	**-145.25**	**-86.10**	**-362.06**	**-1159.73**	**-571.50**
10 Tax Expenses	**0.00**	**-0.39**		**-0.39**	0.00	-
					0.00	
11 Net Profit/(Loss) from Ordinary activities after tax (9±10)	**-148.25**	**-145.64**	**-86.10**	**-362.45**	**-1159.73**	**-571.50**
12 Extraordinary Item (net of tax expenses)	0.00	0.00		0.00	0.00	0.00
13 Net Profit/(Loss) for the period (11±12)	**-148.25**	**-145.64**	**-86.10**	**-362.45**	**-1159.73**	**-571.50**
14 Paid up equity share capital (face value Rs.10/- per share)	2158.00	2158.00	2158.00	2158.00	2158.00	2158.00
15 Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year	0	0	0	0	0	4645.68
16 i. Earnings Per Share (before extraordinary items) (of Rs 10/-each (not annualised)						
(a) Basic	-0.69	-0.67	-0.40	-1.68	-5.37	-2.65
(b) Diluted	-0.69	-0.67	-0.40	-1.68	-5.37	-2.65
16 ii. Earnings Per Share (After extraordinary items) (of Rs 10/-each (not annualised)						
(a) Basic	-0.69	-0.67	-0.40	-1.68	-5.37	-2.65
(b) Diluted	-0.69	-0.67	-0.40	-1.68	-5.37	-2.65

Lyka Labs Limited

MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry @ lykalabs.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st DECEMBER 2012

Particular	3 Months Ended	Previous 3 Months Ended	Corresponding 3 Month ended in the Previous period ended	Year to date figure for Current year Ended	Year to date figure for Previous period Ended	Previous Accounting year Ended
	31-Dec-2012	30-Sep-2012	31-Dec-2011	31-Dec- 2012 (9 Months)	31/12/2011 (15 Months)	31-Mar-2012 (18 Months)
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
A PARTICULARS OF SHAREHOLDING						
1 Public Shareholding						
Number of shares	16552735	16552735	16552735	16552735	16552735	16552735
percentage of shareholding	76.70	76.70	76.70	76.70	76.70	76.70
2 Promoters and promoter group - Shareholding						
a. Pledged / Encumbered						
- Numbers of Shares	4665615	4965615	4981515	4665615	4981515	4965615
- Percentage of shares (as a % of the total shareholding of promoter and promoter group	92.81	98.77	99.09	92.81	99.09	98.77
- Percentage of shares (as a % of the total share capital of the company)	21.62	23.01	23.08	21.62	23.08	23.01
b. Non - encumbered						
- Number of shares	361650	61650	45750	361650	45750	61650
- Percentage of shares (as a % of the total shareholding of promoter and promoter group	7.19	1.23	0.91	7.19	0.91	1.23
- Percentage of shares (as a % of the total share capital of the company)	1.68	0.29	0.22	1.68	0.22	0.29

B	PARTICULARS		
	INVESTOR COMPLAINTS	3 Month Ended	
	Pending at the beginning of the quarter	-	
	Received during the quarter	2	
	Disposed of during the quarter	2	
	Remaining unresolved at the end of the quarter	-	

Contd...3/-..

Notes:

1. The above results were duly considered by the Audit Committee on 14th February, 2013, and taken on record by the Board of Directors of the Company along with Limited Review Report carried out by the Auditors at its meeting held on 14th February, 2013.

2. During the Quarter the Company has charged Rs.19.04 lacs being depreciation on revalued assets.

3. During the Quarter, the Company has capitalised interest of Rs.19.95 lacs towards the Term Loan for Tarapur Upgradation, Ankleshwar Expansion and R & D Unit and Rs.28.39 lacs towards pending allocation to Intangible Assets.

4. The Company's factory at Tarapur is under upgradation. In view of this the production has been suspended.

5. The Company has one Single Segment "Pharmaceuticals".

6. Previous periods figures have been regrouped/rearranged wherever necessary.

7. Audit qualifications in respect of Audited Accounts for 2010-2012 and management comments thereon are detailed below :

   Regarding the Revaluation of its Fixed Assets in the earlier year and writing off/adjustment of stocks, overdue debtors, loans & advances and deferred revenue expenditure, the management is of the view that such extra-ordinary items relating to the past years could legitimately be written off against the 'net present replacement value' and during the year, profit on sale of revalued assets is the "actual profit" realised and the remaining assets belonging to the Company have significantly higher "present replacement values" the management is of the view that such extra-ordinary items is legitimately credited as the Profit on Sale of Assets.

For LYKA LABS LIMITED

(N. I. GANDHI)
Chairman & Managing Director

Mumbai
14-Feb-13